$101.79+45.35% · 3M
Moving avg
1W+21.77%
1M+33.74%
3M+45.35%
6M+28.02%
YTD+44.77%
1Y+58.95%
3Y+132.08%
5Y+144.75%
52-week range
$57.68100% of range$82.26
Company health
Value0/6
Growth6/6
Profitability6/6
Health3/6
Dividend0/6
Bull vs bear
Strengths
- Analyst consensus is "Buy"
- Strong 23% net margin
- High return on equity (12627%)
- Revenue compounding 30% a year
Risks
- Trades 13% above the average analyst target
- Highly leveraged (debt is 43.9x equity)
Key statistics
Valuation
Market cap
$12.07B
Enterprise value
$11.42B
P/E ratio (TTM)
27.68x
P/S ratio (TTM)
6.36x
EV/EBITDA
18.31x
Per share & returns
EPS (TTM)
$2.95
Dividend yield
0.00%
Beta (1Y)
0.84
30-day change
+33.74%
Trading
Volume (24h)
3.48M
Previous close
$102.62
Shares outstanding
118.61M
About Halozyme Therapeutics, Inc.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Symbol
HALO
Halozyme Therapeutics, Inc. is a large-cap healthcare company in the Biotechnology industry. Its shares are listed on NASDAQ (United States) and trade under the ticker HALO.
Frequently asked questions
What is Halozyme Therapeutics, Inc.'s market cap?
Halozyme Therapeutics, Inc. (HALO) has a market capitalization of $12.07B.
What is Halozyme Therapeutics, Inc.'s P/E ratio?
Halozyme Therapeutics, Inc. trades at a price-to-earnings (P/E) ratio of 27.68.
What exchange does HALO trade on?
HALO trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,220.51+0.45%
$1.15T cap
Johnson & JohnsonJNJ
$260.86+0.41%
$628.65B cap
AbbVie Inc.ABBV
$248.66-0.57%
$439.33B cap
UnitedHealth Group IncorporatedUNH
$405.59+0.85%
$368.33B cap
Roche Holding AGSWX: ROP
CHF 365.50-0.92%
$357.68B cap
Merck & Co., Inc.MRK
$132.93+1.92%
$328.31B cap
Novartis AGSWX: NOVN
CHF 124.20-1.32%
$290.23B cap
AstraZeneca PLCLON: AZN
£117.02-1.20%
$244.93B cap